Publication | Open Access

CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial

Hematological MalignancyCell TherapyDose Escalation SegmentCellular TherapiesMedicineHematologyImmunologyAutoimmunityMultiple MyelomaAdult T-cell Leukemia-lymphomaImmunotherapyOncologyCell TransplantationPhase 1